Study S002518

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study To Evaluate The Efficacy And Safety Of DA-302168S Tablets In Overweight/Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06953063
Acronym: DA168
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 250
Start: 2025-05-15
Primary completion: 2025-12-15
Lead sponsor: Chendu DIAO Pharmaceutical Group CO., LTD.
Conditions: Overweight and Obesity
Interventions: DRUG:DA-302168S; DRUG:Placebo of DA-302168S
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

percentage change in body weight [From baseline (week1) to week16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.